ReviewFrontiers in bioscience (Scholar edition)2011
Cognition, dopamine and bioactive lipids in schizophrenia.
Review in Frontiers in bioscience (Scholar edition), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 68 citations in OpenAlex.
- Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial.Schizophrenia research · 2021Trial
- Association between theSchizophrenia research. Cognition · 2024Article
- Lipid-correlated alterations in the transcriptome are enriched in several specific pathways in the postmortem prefrontal cortex of Japanese patients with schizophrenia.Neuropsychopharmacology reports · 2023Article
- Actualities in immunological markers and electrochemical sensors for determination of dopamine and its metabolites in psychotic disorders (Review).Experimental and therapeutic medicine · 2021Review
- Interactive effect ofAging · 2020Observational
- Association of regulatory variants of dopamine β-hydroxylase with cognition and tardive dyskinesia in schizophrenia subjects.Journal of psychopharmacology (Oxford, England) · 2020Article
- Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases.Prostaglandins, leukotrienes, and essential fatty acids · 2018Review
- Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.The American journal of psychiatry · 2018Article
- Neurosteroids in Schizophrenia: Pathogenic and Therapeutic Implications.Frontiers in psychiatry · 2018Review
- Stereopsis deficits in patients with schizophrenia in a Han Chinese population.Scientific reports · 2017Article
- The dopamine beta-hydroxylase gene polymorphism rs1611114 is associated with schizophrenia in the Chinese Zhuang but not Chinese Han population.Molecular genetics and genomics : MGG · 2016Article
- The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.Molecular neurobiology · 2016Review
- Benzotriazole: An overview on its versatile biological behavior.European journal of medicinal chemistry · 2015Review
- Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia.Psychopharmacology · 2015Article
- Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia.Schizophrenia bulletin · 2014Article
- Inflammation and the two-hit hypothesis of schizophrenia.Neuroscience and biobehavioral reviews · 2014Review
- Dopaminergic gene polymorphisms and cognitive function in a north Indian schizophrenia cohort.Journal of psychiatric research · 2013Article
- Article
- Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.Psychopharmacology · 2012Article
- Aptamers for pharmaceuticals and their application in environmental analytics.Bioanalytical reviews · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Schizophrenia is a remarkably complex disorder with a multitude of behavioral and biological perturbations. Cognitive deficits are a core feature of this disorder, and involve abnormalities across multiple domains, including memory, attention, and perception. The complexity of this debilitating illness has led to a view that the key to unraveling its pathophysiology lies in deconstructing the clinically-defined syndrome into pathophysiologically distinct intermediate phenotypes. Accumulating evidence suggests that one of these intermediate phenotypes may involve phospholipid signaling abnormalities, particularly in relation to arachidonic acid (AA). Our data show relationships between levels of AA and performance on tests of cognition for schizophrenia patients, with defects in AA signaling associated with deficits in cognition. Moreover, dopamine may moderate these relationships between AA and cognition. Taken together, cognitive deficits, dopaminergic neurotransmission, and bioactive lipids have emerged as related features of schizophrenia. Existing treatment options for cognitive deficits in schizophrenia do not specifically target lipid-derived signaling pathways; understanding these processes could inform efforts to identify novel targets for treatment innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.